Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.

ABSTRACT: Personalized dendritic cell- (DC-) based vaccination has proven to be safe and effective as second-line therapy against various cancer types. In terms of overall survival, there is still room for improvement of DC-based therapies, including the development of more immunostimulatory DC vaccines. In this context, we redesigned our currently clinically used DC vaccine generation protocol to enable transpresentation of interleukin- (IL-) 15 to IL-15Rβγ-expressing cells aiming at boosting the antitumor immune response. In this study, we demonstrate that upon electroporation with both IL-15 and IL-15Rα-encoding messenger RNA, mature DC become highly positive for surface IL-15, without influencing the expression of prototypic mature DC markers and with preservation of their c

SUBMITTER: Van den Bergh JMJ 

PROVIDER: S-EPMC5530419 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature